The KEAPSAKE trial was a phase 2 randomized multicenter double-blind clinical trial comparing the addition of the glutaminase inhibitor CB-839 or placebo control to standard of care checkpoint blockade and chemotherapy for patients with metastatic NSCLC with KEAP1 or NRF2 mutations. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.